Sofieke J. D. Temmink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofieke J. D. Temmink has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Andrew G Renehan
Manchester Cancer Research Centre, National Institute of Health Research Manchester Biomedical Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine, and Health, University of Manchester , Manchester , UK
2 shared publications- Anna Martling
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
2 shared publications Koen C M J Peeters
Department of Surgery, Leiden University Medical Center , Leiden , The Netherlands
2 shared publicationsOriol Pares
Department of Radiation Oncology, Champalimaud Foundation , Lisboa , Portugal
2 shared publicationsPer J Nilsson
Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm , Sweden
2 shared publications- Per Johan Nilsson
Department of Pelvic Cancer, Karolinska University Hospital , Stockholm
2 shared publications
Latest Publications
- Open Access
Surgical Outcomes after Radiotherapy in Rectal Cancer
Over the past decade, the treatment of rectal cancer has changed considerably. The implementation of TME surgery has, in addition to decreasing the number of local recurrences, improved surgical morbidity and mortality. At the same time, the optimisation of radiotherapy in the preoperative setting has improved oncological outcomes even further, although higher perineal infection rates have been reported. Radiotherapy regimens have evolved through the adjustment of radiotherapy techniques and fields, increased waiting intervals, and, for more advanced tumours, adding chemotherapy. Concurrently, imaging techniques have significantly improved staging accuracy, facilitating more precise selection of advanced tumours. Although chemoradiotherapy does lead to the downsizing and -staging of these tumours, a very clear effect on sphincter-preserving surgery and the negative resection margin has not been proven. Aiming to decrease distant metastasis and improve overall survival for locally advanced rectal cancer, systemic chemotherapy can be added to radiotherapy, known as total neoadjuvant treatment (TNT). High complete response rates, both pathological (pCR) and clinical (cCR), are reported after TNT. Patients who follow a Watch & Wait program after a cCR can potentially avoid surgical morbidity and colostomy. For both early and more advanced tumours, trials are now investigating optimal regimens in an attempt to offer organ preservation as much as possible. Multidisciplinary deliberation should include patient preference, treatment toxicity, and likelihood of end colostomy, but also the burden of intensive surveillance in a W&W program.
Open AccessSurgical Outcomes after Radiotherapy in Rectal Cancer
Over the past decade, the treatment of rectal cancer has changed considerably. The implementation of TME surgery has, in addition to decreasing the number of local recurrences, improved surgical morbidity and mortality. At the same time, the optimisation of radiotherapy in the preoperative setting has improved oncological outcomes even further, although higher perineal infection rates have been reported. Radiotherapy regimens have evolved through the adjustment of radiotherapy techniques and fields, increased waiting intervals, and, for more advanced tumours, adding chemotherapy. Concurrently, imaging techniques have significantly improved staging accuracy, facilitating more precise selection of advanced tumours. Although chemoradiotherapy does lead to the downsizing and -staging of these tumours, a very clear effect on sphincter-preserving surgery and the negative resection margin has not been proven. Aiming to decrease distant metastasis and improve overall survival for locally advanced rectal cancer, systemic chemotherapy can be added to radiotherapy, known as total neoadjuvant treatment (TNT). High complete response rates, both pathological (pCR) and clinical (cCR), are reported after TNT. Patients who follow a Watch & Wait program after a cCR can potentially avoid surgical morbidity and colostomy. For both early and more advanced tumours, trials are now investigating optimal regimens in an attempt to offer organ preservation as much as possible. Multidisciplinary deliberation should include patient preference, treatment toxicity, and likelihood of end colostomy, but also the burden of intensive surveillance in a W&W program.
- Open Access
- 20 July 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106991
Complete response rates in rectal cancer: Temporal changes over a decade in a population-based nationwide cohort
- 20 July 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106991
Open AccessComplete response rates in rectal cancer: Temporal changes over a decade in a population-based nationwide cohort
- Open Access
- 22 June 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (9) , 1242
Author response to: Comment on: Outcomes following watch and wait of a clinical complete response in rectal cancer after neoadjuvant treatment: comparison of patients with and without complete response at first reassessment in the International Watch & Wait Database (IWWD)
Dear Editor
- 22 June 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (9) , 1242
Open AccessAuthor response to: Comment on: Outcomes following watch and wait of a clinical complete response in rectal cancer after neoadjuvant treatment: comparison of patients with and without complete response at first reassessment in the International Watch & Wait Database (IWWD)
Dear Editor
- Open Access
- 27 March 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 676-684
Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD)
In rectal cancer, watch and wait for patients with a cCR after neoadjuvant treatment has an established evidence base. However, there is a lack of consensus on the definition and management of a near-cCR. This study aimed to compare outcomes in patients who achieved a cCR at first reassessment versus later reassessment. This registry study included patients from the International Watch & Wait Database. Patients were categorized as having a cCR at first reassessment or at later reassessment (that is near-cCR at first reassessment) based on MRI and endoscopy. Organ preservation, distant metastasis-free survival, and overall survival rates were calculated. Subgroup analyses were done for near-cCR groups based on the response evaluation according to modality. A total of 1010 patients were identified. At first reassessment, 608 patients had a cCR; 402 had a cCR at later reassessment. Median follow-up was 2.6 years for patients with a cCR at first reassessment and 2.9 years for those with a cCR at later reassessment. The 2-year organ preservation rate was 77.8 (95 per cent c.i. 74.2 to 81.5) and 79.3 (75.1 to 83.7) per cent respectively (P = 0.499). Similarly, no differences were found between groups in distant metastasis-free survival or overall survival rate. Subgroup analyses showed a higher organ preservation rate in the group with a near-cCR categorized exclusively by MRI. Oncological outcomes for patients with a cCR at later reassessment are no worse than those of patients with a cCR at first reassessment.
- 27 March 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (6) , 676-684
Open AccessWatch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD)
In rectal cancer, watch and wait for patients with a cCR after neoadjuvant treatment has an established evidence base. However, there is a lack of consensus on the definition and management of a near-cCR. This study aimed to compare outcomes in patients who achieved a cCR at first reassessment versus later reassessment. This registry study included patients from the International Watch & Wait Database. Patients were categorized as having a cCR at first reassessment or at later reassessment (that is near-cCR at first reassessment) based on MRI and endoscopy. Organ preservation, distant metastasis-free survival, and overall survival rates were calculated. Subgroup analyses were done for near-cCR groups based on the response evaluation according to modality. A total of 1010 patients were identified. At first reassessment, 608 patients had a cCR; 402 had a cCR at later reassessment. Median follow-up was 2.6 years for patients with a cCR at first reassessment and 2.9 years for those with a cCR at later reassessment. The 2-year organ preservation rate was 77.8 (95 per cent c.i. 74.2 to 81.5) and 79.3 (75.1 to 83.7) per cent respectively (P = 0.499). Similarly, no differences were found between groups in distant metastasis-free survival or overall survival rate. Subgroup analyses showed a higher organ preservation rate in the group with a near-cCR categorized exclusively by MRI. Oncological outcomes for patients with a cCR at later reassessment are no worse than those of patients with a cCR at first reassessment.